Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death

(2012) Jamie A. Lopez et al.   TRENDS IN IMMUNOLOGY

The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy

(2012) Asís Palazón et al.   Cancer Discovery

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis

(2010) Luis Martinez-Lostao et al.   ARTHRITIS AND RHEUMATISM

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

(2009) Oihana Murillo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation

(2009) Julián Pardo et al.   MICROBES AND INFECTION

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma

(2008) O. Murillo et al.   CLINICAL CANCER RESEARCH